After-hours Gainers: HOWL Jumps 90%, MODD To Begin Pivot Pump Rollout, BIVI Awaits Long COVID Data

Werewolf Therapeutics (HOWL) rose 90% in after-hours trading, with key clinical trials ongoing. GeoVax (GOVX) gained 12.66%, preparing for a pivotal Phase 3 study. Greenwich LifeSciences (GLSI) increased 6.27%, extending share lock-up. Modular Medical (MODD) up 7.87%, planning Pivot pump rollout. Ovid Therapeutics (OVID) rose 6.93%, with multiple clinical milestones. BioVie (BIVI) up 4.84%, awaiting long COVID data.

Original reporting
Published Aug 21, 2026, 3:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 3:15 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$HOWL
Bullish
high confidence
Mentioned
$HOWL · $GOVX · $MODD · $OVID · $BIVI · $GLSI
Relevance
6/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$HOWLBullishMed
01

Why it matters

The article reports fresh, primary information on trial enrollments, upcoming pivotal studies, and commercial rollout plans, leading to notable price moves across several small‑cap biotech stocks.

02

Market read

Multiple small‑cap biotech stocks experienced sharp after‑hours gains driven by fresh trial and commercialisation news, indicating short‑term trading opportunities.

03

What to watch

Potential dilution from future financing rounds and regulatory hurdles for trial candidates.

Relevance 6/10Novelty 6/10Timing: after‑hours today

Background

After‑hours trading often reflects immediate reaction to company‑specific news, especially in biotech where trial updates drive volatility.

Company-level read

Ticker impact

$HOWLBullishHigh confidence
Context

After-hours the stock surged 90% to $0.81 following news of ongoing Phase 1/1b trials of WTX-124 and enrollment in a Phase 1b/2 trial for WTX-330.

Expected impact

Potential further upside if trial data are released; watch for volatility.

Evidence & confidence

Large after‑hours price jump on fresh trial enrollment news suggests traders may chase momentum.

$GOVXBullishMedium confidence
Context

GOVX rose 12.66% in after‑hours to $0.67 after confirming a Phase 3 GEO‑MVA immune‑bridging study will start next quarter.

Expected impact

Likely continued rally if trial initiation proceeds as planned.

Evidence & confidence

Trial initiation news is material for a biotech with limited pipeline.

$MODDBullishMedium confidence
Context

MODD gained 7.87% in after‑hours to $3.70 as it announced the first phase of commercialisation of its Pivot tubeless patch pump in five U.S. markets starting October 2026.

Expected impact

Further upside possible as rollout details emerge.

Evidence & confidence

Commercialisation plans for a novel medical device can drive investor interest.

$OVIDBullishMedium confidence
Context

OVID rose nearly 7% after‑hours to $2.93, citing multiple upcoming clinical milestones for OV4071 and OV329, including a Phase 1 trial data timeline and a ketamine challenge study.

Expected impact

Potential upside if early data are positive; watch for volatility.

Evidence & confidence

Biotech stocks often react to announced trial timelines.

$BIVIBullishMedium confidence
Context

BIVI climbed 4.84% in after‑hours to $1.95 as it highlighted a Phase 2 ADDRESS‑LC study for long‑COVID cognitive impairment with topline results expected late summer 2026.

Expected impact

Further gains possible if trial data are encouraging.

Evidence & confidence

Long‑COVID is a high‑interest therapeutic area; trial updates can move the stock.

$GLSINeutralLow confidence
Context

GLSI rose over 6% after‑hours to $16.27 after reporting a lock‑up extension for insiders and pre‑IPO investors to Jan 2027.

Expected impact

Limited impact; price may stabilize.

Evidence & confidence

Lock‑up extensions are modest news for a late‑stage biotech.

Market effects

Biotech sector may see broader rally as multiple companies report trial progress.

U.S. biotech stocks gain momentum in after‑hours trading.

Limited to U.S. listed biotech firms; no immediate global macro effect.

Counterpoint

Price spikes may be short‑lived without concrete data releases; risk of pull‑back.

Key entities

  • Werewolf Therapeutics

    Biotech developing conditionally activated cancer therapeutics.

  • GeoVax Labs

    Vaccine platform company advancing GEO‑MVA and other candidates.

  • Modular Medical

    Medical‑device maker launching a tubeless insulin pump.

  • Ovid Therapeutics

    Biotech focusing on CNS disorders with pipeline OV4071/OV329.

  • BioVie

    Developer of Bezisterim for long‑COVID and Parkinson's.

Related articles

$GLSIMedAI 8/10

RedChip Companies, Inc.: Greenwich LifeSciences Interview to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV

Greenwich LifeSciences (GLSI) will be featured on the RedChip Small Stocks, Big Money show on Bloomberg TV and CNBC. CEO Snehal Patel discusses GLSI-100, an immunotherapy for HER2-positive breast cancer, highlighting an 80% reduction in recurrence in trials. The company is expanding its Phase III trial and exploring broader patient eligibility. GLSI aims to double its target population to 88,000 patients in the U.S. and Europe.

$GLSIMedAI 8/10

Greenwich LifeSciences presents at BIO-Europe 2026 in Cologne

Greenwich LifeSciences (GLSI) presented at BIO-Europe 2026, discussing its phase three trial (Flamingo-1) for early breast cancer. The trial, led by Baylor College of Medicine, has 180 sites in the US and Europe, with plans to expand. The company reported an 80% reduction in recurrence rate in phase two trials. GLSI is publicly traded, has raised $60M since IPO, and is fast track designated. Management owns 75-85% of the company, with a low float and extended lockup until January 2027.